# US 2015/0030589 A1 · Abeta antibody formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0030589 A1
- Document ID: US20150030589A1
- Status: Published application
- Kind: A1
- Application number: 14/381,849
- Filed: 2013-03-05
- Published: 2015-01-29
- Earliest claimed: 2012-03-08
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Pierre Goldbach; Hanns-Christian Mahler; Robert Mueller
- Web page: https://patentgrep.com/patent/US20150030589A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39591: {Stabilisation, fragmentation}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/565: Complementarity determining region [CDR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a pharmaceutical formulation comprising about 50 mg/ml-200 mg/ml of an Abeta antibody, about 0.01%-0.1% poloxamer, about 5 mM-50 mM of a buffer, about 100 mM-300 mM of a stabilizer at a pH of about 4.5-7.0.

## Claims

### Claim 1

A stable liquid pharmaceutical antibody formulation comprising:
about 50 mg/ml-200 mg/ml of an Abeta antibody,
about 0.01%-0.1% of a poloxamer, preferably poloxamer 188,
about 5 mM-50 mM of a buffer,
about 100 mM-300 mM of a stabilizer,
wherein the formulation has a pH of about 4.5-7.0

### Claim 2 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the Abeta antibody concentration is about 100 mg/ml-200 mg/ml.

### Claim at position 3

3-18. (canceled)

### Claim 19 (depends on 2)

The formulation according to claim 2, wherein the Abeta antibody concentration is about 150 mg/ml.

### Claim 20 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the poloxamer is present in a concentration of about 0.02%-0.06%.

### Claim 21 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the poloxamer is present in a concentration of about 0.02%-0.06%.

### Claim 22 (depends on 19)

The formulation according to claim 19, wherein the poloxamer is about 0.04%.

### Claim 23 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 24 (depends on 23)

The pharmaceutical formulation according to claim 23, wherein the buffer is a Histidine buffer.

### Claim 25 (depends on 2)

The pharmaceutical formulation according to claim 2, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 26 (depends on 3)

The pharmaceutical formulation according to claim 3, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 27 (depends on 19)

The pharmaceutical formulation according to claim 19, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 28 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 29 (depends on 21)

The pharmaceutical formulation according to claim 21, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 30 (depends on 22)

The pharmaceutical formulation according to claim 22, wherein the buffer is a sodium acetate buffer or a Histidine buffer.

### Claim 31 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 32 (depends on 2)

The pharmaceutical formulation according to claim 2, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 33 (depends on 23)

The pharmaceutical formulation according to claim 23, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 34 (depends on 24)

The pharmaceutical formulation according to claim 24, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 35 (depends on 25)

The pharmaceutical formulation according to claim 25, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 36 (depends on 26)

The pharmaceutical formulation according to claim 26, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 37 (depends on 27)

The pharmaceutical formulation according to claim 27, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 38 (depends on 22)

The pharmaceutical formulation according to claim 22, wherein the buffer has a concentration of about 10 to 30 mM.

### Claim 39 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the pH of the formulation is about 5-6.

### Claim 40 (depends on 2)

The pharmaceutical formulation according to claim 2, wherein the pH of the formulation is about 5-6.

### Claim 41 (depends on 19)

The pharmaceutical formulation according to claim 19, wherein the pH of the formulation is about 5-6.

### Claim 42 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the pH of the formulation is about 5-6.

### Claim 43 (depends on 19)

The pharmaceutical formulation according to claim 19, wherein the pH of the formulation is about 5-6.

### Claim 44 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the pH of the formulation is about 5-6.

### Claim 45 (depends on 21)

The pharmaceutical formulation according to claim 21, wherein the pH of the formulation is about 5-6.

### Claim 46 (depends on 22)

The pharmaceutical formulation according to claim 22, wherein the pH of the formulation is about 5-6.

### Claim 47 (depends on 23)

The pharmaceutical formulation according to claim 23, wherein the pH of the formulation is about 5-6.

### Claim 48 (depends on 24)

The pharmaceutical formulation according to claim 24, wherein the pH of the formulation is about 5-6.

### Claim 49 (depends on 25)

The pharmaceutical formulation according to claim 25, wherein the pH of the formulation is about 5-6.

### Claim 50 (depends on 26)

The pharmaceutical formulation according to claim 26, wherein the pH of the formulation is about 5-6.

### Claim 51 (depends on 27)

The pharmaceutical formulation according to claim 27, wherein the pH of the formulation is about 5-6.

### Claim 52 (depends on 28)

The pharmaceutical formulation according to claim 28, wherein the pH of the formulation is about 5-6.

### Claim 53 (depends on 29)

The pharmaceutical formulation according to claim 29, wherein the pH of the formulation is about 5-6.

### Claim 54 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the stabilizer is selected from sugars and amino acids.

### Claim 55 (depends on 2)

The pharmaceutical formulation according to claim 2, wherein the stabilizer is selected from trehalose and arginine.

### Claim 56 (depends on 19)

The pharmaceutical formulation according to claim 19, wherein the stabilizer is arginine and has a concentration of about 100 mM to 150 mM.

### Claim 57 (depends on 20)

The pharmaceutical formulation according to claim 20, wherein the stabilizer is arginine and has a concentration of about 100 mM to 150 mM.

### Claim 58 (depends on 21)

The pharmaceutical formulation according to claim 21, wherein the stabilizer is arginine and has a concentration of about 100 mM to 150 mM.

### Claim 59 (depends on 22)

The pharmaceutical formulation according to claim 22, wherein the stabilizer is arginine and has a concentration of about 100 mM to 150 mM.

### Claim 60 (depends on 1)

The pharmaceutical formulation according to claim 1, wherein the Abeta antibody is a monoclonal antibody comprising a heavy chain and a light chain.

### Claim 61 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the heavy chain of the Abeta antibody comprises a VH domain which comprises:
a CDR1 comprising the amino acid sequence of Seq. Id. No. 4,
a CDR2 comprising the amino acid sequence of Seq. Id. No. 5, and
a CDR3 sequence comprising the amino acid sequence of Seq. Id. No. 6.

### Claim 62 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the light chain of the Abeta antibody comprises a VL domain which comprises:
a CDR1 comprising the amino acid sequence of Seq. Id. No. 7,
a CDR2 comprising the amino acid sequence of Seq. Id. No. 8,
a CDR3 sequence comprising the amino acid sequence of Seq. Id. No. 9.

### Claim 63 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the light chain of the Abeta antibody comprises a VL domain which comprises:
a CDR1 comprising the amino acid sequence of Seq. Id. No. 7,
a CDR2 comprising the amino acid sequence of Seq. Id. No. 8,
a CDR3 sequence comprising the amino acid sequence of Seq. Id. No. 9.

### Claim 64 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the heavy chain of the Abeta antibody comprises a VH domain which comprises:
a CDR1 comprising the amino acid sequence of Seq. Id. No. 4,
a CDR2 comprising the amino acid sequence of Seq. Id. No. 5, and
a CDR3 sequence comprising the amino acid sequence of Seq. Id. No. 6.

### Claim 65 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the VH domain of the Abeta antibody comprises the amino acid sequence of Seq. Id. No. 2 and the VL domain of the Abeta antibody comprises the amino acid sequence of Seq. Id. No. 3.

### Claim 66 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the heavy chain of the Abeta antibody comprises the amino acid sequence of Seq. Id. No. 10.

### Claim 67 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the heavy chain of the Abeta antibody comprises the amino acid sequence of Seq. Id. No. 10.

### Claim 68 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein light chain of the Abeta antibody comprises the amino acid sequence of Seq. Id. No. 11.

### Claim 69 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.

### Claim 70 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.

### Claim 71 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.

### Claim 72 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.

### Claim 73 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.

### Claim 74 (depends on 60)

The pharmaceutical formulation according to claim 60, wherein the monoclonal Abeta antibody comprises: a mixture of mono-glycosylated Abeta antibodies and double-glycosylated Abeta antibodies; and wherein the mono-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of one antibody binding site and wherein the double-glycosylated antibody comprises a glycosylated asparagine (Asn) at position 52 of Seq. Id. No. 2 in the VH domain of both antibody binding sites and whereby said mixture comprises less than 5% of an antibody being non-glycosylated at position 52 of Seq. Id. No. 2 in the VH domain.
